The Effect of Dexmedetomidine in the Management of Pain After Uterine Artery Embolization

Pain Control Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01578174
• Other study ID #: 4-2011-0928
• Status: Completed
• Phase: N/A
• First received: April 13, 2012
• Last updated: January 16, 2018
• Start date: April 2012
• Est. completion date: September 2012

Study information

• Verified date: January 2018
• Source: Severance Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators examined the effect of dexmedetomidine in the management of pain after uterine artery embolization.

Description:

Leiomyoma are the most common female reproductive tract tumors. Uterine artery embolization(UAE) is a minimally invasive treatment alternative to hysterectomy and myomectomy. However, post-procedural pain control after UAE remains a major problem. Therefore, the aim of study is to evaluate the efficacy of dexmedetomidine in pain control after UAE.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• age = 20,

• ASA class I and II

Exclusion Criteria:

• bradycardia (< 45 bpm)

• heart block

• liver failure

• renal failure

• uncontrolled hypertension

• body mass index = 30 kg/m2

Related Conditions & MeSH terms

• Pain Control

Intervention

Drug:
• Dexmedetomidine
Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -> 2?/mL) : the infusion of 0.2?/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4?/kg/hr after completion of procedure
• Normal saline 0.9%
Normal saline 100mL(guess as 2?/mL):the infusion of 0.2?/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4?/kg/hr after completion of procedure

Locations

Country	Name	City	State
Korea, Republic of	Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Severance Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fentanyl consumption by patient-controlled analgesia		24 hours
Secondary	Side effects		24 hours